Vilin Bio Med (VILINBIO)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 115.14% shows strong demand traction for its products.
• Promoter holding of 59.57% aligns management interests with minority shareholders.
• Piotroski F-Score of 7/9 suggests improving operational efficiency and financial health in recent periods.
• Small market cap of ₹49 crore offers a potential niche upside if the business matures profitably.

Concerns

• P/E of 195.04 implies minuscule earnings of roughly ₹0.25 crore, making the valuation extremely expensive.
• Latest quarter net profit of ₹0 crore on ₹10 crore sales indicates negligible margins or one-off issues.
• ROCE of just 4.20% is far below any acceptable return on invested capital.
• No dividend and insufficient data on book value/debt make a Graham-style margin-of-safety analysis impossible.

AI Analysis

At ₹37, Vilin Bio Med commands a market cap of only ₹49 crore. That is small, and high promoter holding of 59.57% is a plus. But as Graham taught, a stock is not an investment just because it is small. The trailing P/E of 195.04 implies earnings of roughly ₹0.25 crore on a ₹49 crore market cap. That is far too rich for a business earning a ROCE of just 4.20%. Sales growth of 115.14% looks wonderful, yet latest quarter sales of ₹10 crore produced zero net profit. Revenue without profit is not business quality; it is just turnover. Profit growth of 25% is far behind sales growth, and the PEG of 2.78 underscores that you are paying a premium for growth that is not translating to the bottom line. There is no dividend to compensate. The Piotroski F-Score of 7/9 suggests some balance-sheet improvement, but with no book value or debt-equity ratio available, I cannot judge financial health properly. The 52-week range of ₹18.95 to ₹54.40 shows the stock has already been a wild ride. As Buffett would say, it is far better to buy a wonderful company at a fair price than a questionable company at any price. Vilin may be growing sales, but without a moat or pricing power, that growth is fragile. I need to see consistent profitability and tangible return on capital before I can call this a genuine value proposition. For now, this is a speculation on a fast-growing, low-margin pharma business, not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer